AgaPharm is developing a prescription eye drop that Diabetics will use daily for the rest of their lives. Our drug will offer a simple, low-cost treatment that can deliver a safe and effective dose to the eye, preventing or slowing down the onset of diabetic blindness and cataract. Our Research Partner is the Biotechnology Research Institute at the National Research Council – the Government of Canada's premier organization for research and development.

Mark Adam, Chief Executive Officer and Founder (B.A., B.Sc., M.B.A)
Mark Adam brings extensive experience in building teams and an intimate knowledge of finance, risk management and intellectual property to AgaPharm. Mr. Adam recently spent four years, much of it as CFO, with an optical component company that he helped found. He was instrumental in securing two rounds of venture financing worth over $24M. His career also includes relevant experience at the Pharmaceutical Manufacturers Association of Canada and at Leo Pharma. He holds two degrees in science, and an MBA from Cornell University.

Dr. Yasuo Konishi (Ph.D.)
Dr. Konishi is a Senior Research Officer with Canada’s Biotechnology Research Institute. He obtained a Ph.D. in Chemistry from Tohoku University in 1976, followed by postdoctoral training at Cornell University. He has patented over 15 biomedical compounds or assays.

David Justinich, Director Corporate Services (B.A., M.A.)
David Justinich has built a successful twenty-three year career leading teams and managing projects and risk in complex environments. Most recently, Mr. Justinich coordinated strategic communications for an optical component company, and managed all marketing activities. He was also responsible for public, investor and analyst relations.

Research Partner – National Research Council of Canada’s Biotechnology Research Institute
This technology was developed at the National Research Council (NRC) of Canada’s Biotechnology Research Institute (BRI). The National Research Council is the Government of Canada's premier organization for research and development, operating since 1916. NRC employs close to 4,000 people across Canada, providing substantial resources to create world class R&D initiatives. The Biotechnology Research Institute’s multidisciplinary research teams are active in three main sectors: Health, Bioprocess and Environment. In the field of life sciences, their expertise forms a continuum that includes drug discovery, bioprocess development and scale-up.

The NRC and BRI will continue to be an active partner as this technology progresses through preclinical trials.